Posted by Michael Wonder on 19 May 2021
NICE terminates yet another appraisal of a cancer medicine
19 May 2021 - This time it is for a new medicine for patients with multiple myeloma.
NICE is unable to make a recommendation on the use of selinexor for use in combination with low-dose dexamethasone for the treatment of adults with refractory multiple myeloma because Karyopharm Therapeutics did not provide an evidence submission.
As usual, NICE will review this decision if Karyopharm Therapeutics decides to make a submission.
